Pesquisas alternativas:
disease novel » disease notes (Expandir a Pesquisa), disease new (Expandir a Pesquisa)
novel fathers » novel factors (Expandir a Pesquisa), novel faces (Expandir a Pesquisa), novel faster (Expandir a Pesquisa)
disease liver » disease like (Expandir a Pesquisa), disease linked (Expandir a Pesquisa), disease living (Expandir a Pesquisa)
drug disease » drug release (Expandir a Pesquisa)
liver theory » linear theory (Expandir a Pesquisa), layer theory (Expandir a Pesquisa), laser theory (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
disease novel » disease notes (Expandir a Pesquisa), disease new (Expandir a Pesquisa)
novel fathers » novel factors (Expandir a Pesquisa), novel faces (Expandir a Pesquisa), novel faster (Expandir a Pesquisa)
disease liver » disease like (Expandir a Pesquisa), disease linked (Expandir a Pesquisa), disease living (Expandir a Pesquisa)
drug disease » drug release (Expandir a Pesquisa)
liver theory » linear theory (Expandir a Pesquisa), layer theory (Expandir a Pesquisa), laser theory (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
1
Por Waalewijn, Hylke, Turkova, Anna, Rakhmanina, Natella, Cressey, Tim R., Penazzato, Martina, Colbers, Angela, Burger, David M.
Publicado no Ther Drug Monit (2019)
“... therapeutic drug monitoring in optimizing the dosing of ARVs in children. METHODS: A PubMed search...”Publicado no Ther Drug Monit (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
“... years and 65 years and older, and between those treated with a low and a high dose of each drug...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
“..., BMI, drug dose and time from drug intake were recorded. RESULTS: All patients had a measurable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... a novel mechanism for the control of disulfide-based drug release rates. Therapy experiments...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Sullivan, David J., Liu, Yi, Mott, Bryan T., Kaludov, Nikola, Martinov, Martin N.
Publicado no PLoS One (2015)
“... computational process for drug discovery and design bridges this gap between theory and practice, and allows...”Publicado no PLoS One (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Kosilov, Kirill Vladimirovich, Loparev, Sergey, Kuzina, Irina, Shakirova, Olga, Zhuravskaya, Nataliya, Lobodenko, Alexandra
Publicado no Ther Adv Urol (2016)
“... in antimuscarinic (AM) drug treatment. BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average...”Publicado no Ther Adv Urol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
“... Disorders -- Dreams and Nightmares -- Drug abuse in cardiovascular diseases -- Liver Disease -- Hyperkinetic...”
Obter o texto integral
Obter o texto integral
Livro
9
“... response, lower the risk that drug resistance will develop, and reduce morbidity and mortality. Little...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Djobet, M. P. Ngogang, Singhe, David, Lohoue, Julienne, Kuaban, Christopher, Ngogang, Jeanne, Tambo, Ernest
Publicado no AIDS Res Ther (2017)
“.... ARVs drugs samples included Nevirapine, Efavirenz, and fixed dose combinations of Zidovudine...”Publicado no AIDS Res Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
“...BACKGROUND: Abnormal states in human liver metabolism are major causes of human liver diseases...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Vornov, James J., Wozniak, Krystyna M., Wu, Ying, Rojas, Camilo, Rais, Rana, Slusher, Barbara S.
Publicado em 2013
Assuntos:
“...Drug Discovery and Translational Medicine...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Goláň, Lubor, Goker-Alpan, Ozlem, Holida, Myrl, Kantola, Ikka, Klopotowski, Mariusz, Kuusisto, Johanna, Linhart, Aleš, Musial, Jacek, Nicholls, Kathleen, Gonzalez-Rodriguez, Derlis, Sharma, Reena, Vujkovac, Bojan, Chang, Peter, Wijatyk, Anna
Publicado no Drug Des Devel Ther (2015)
“... years) with Fabry disease. Inclusion criteria were left ventricular hypertrophy at baseline, defined...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Kuczynski, Elizabeth A., Yin, Melissa, Bar-Zion, Avinoam, Lee, Christina R., Butz, Henriett, Man, Shan, Daley, Frances, Vermeulen, Peter B., Yousef, George M., Foster, F. Stuart, Reynolds, Andrew R., Kerbel, Robert S.
Publicado no J Natl Cancer Inst (2016)
“... hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain...”Publicado no J Natl Cancer Inst (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
“... for therapeutic drug monitoring in clinical settings for Korean adult patients receiving living donor liver...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Talifu, Ainiwaer, Saimaiti, Refuhati, Maitinuer, Yusufu, Liu, Geyu, Abudureyimu, Miernisha, Xin, Xuelei
Publicado no Sci Rep (2019)
“...The pathogenesis of acute liver injury has been plagued by biologists and physicians. We know...”Publicado no Sci Rep (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Yovich, John L, Alsbjerg, Birgit, Conceicao, Jason L, Hinchliffe, Peter M, Keane, Kevin N
Publicado no Drug Des Devel Ther (2016)
“...The first PIVET algorithm for individualized recombinant follicle stimulating hormone (rFSH) dosing...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Nygaard, Haakon B, Wagner, Allison F, Bowen, Garrett S, Good, Susan P, MacAvoy, Martha G, Strittmatter, Kurt A, Kaufman, Adam C, Rosenberg, Brian J, Sekine-Konno, Tomoko, Varma, Pradeep, Chen, Kewei, Koleske, Anthony J, Reiman, Eric M, Strittmatter, Stephen M, van Dyck, Christopher H
Publicado no Alzheimers Res Ther (2015)
“... at doses of 50 mg, 100 mg, 125 mg, or placebo daily for 4 weeks. The drug:placebo ratio was 3:1. Primary...”Publicado no Alzheimers Res Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“... diseases. One of such drugs is Tarix, which was FDA approved and announced in 2016 for treatment of MDC1A...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Zhou, Tao, Zhang, Xia, Dong, Yan, Zhuang, Feifei, Jiang, Fengquan, Yu, Jinming, Zhang, Bin
Publicado no Drug Des Devel Ther (2016)
“... practitioners. Nearly all patients with malignant tumors suffer pain at the advanced stage of their disease...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo